This type of challenge will continue. Hayman Capitol is using a new process called "inter party review.' Acorda gets most of their revenue from Ampra, a treatment for multiple sclerosis. One common ingredient was once used as bird poison. The petition if accepted, may allow eight other generic firms to also challenge Ampra's patents. But even if Hayman is successful in their partition against Ampra, it's still has protection until 2027. Acorda also has other drugs in the pipeline plus acquisitions on tap. Their is no reason for the drop in stock price. Earnings were excellent and should continue.jmo
Sentiment: Strong Buy
I don't think if you are short a stock it should be legal for you to take actions that harm the company whose stock you are short of.It just doesn't seem right or ethical.I'm surprised there isn't a law against it.
....as much integrity as a trolling class action law firm , try to make something out of nothing and in the end the only ones who win are the lawyers, or in the case of of ACOR , bss's hedge fund. What is worse, CNBC a "supposed" unbiased network, wink, wink, further promotes his tactics. Such is the societal and legal structure in the US....Win at any cost , no matter how vile or dishonest the means.......jmho
This was pulled off with the IP patents in the internet world. Who knows how the republican backed guys will work it. I am sure, as with IP protection, some end up looking foolish as friends with this type...
I do know the ip area was a different bird. But, when you allow big corp to run things this is what happens. Goog, Facebook and the like wanted no part of patent protection suits, thus supreme court ruled against small guys. Now everything is stolen for free.
edical is the next logical area to hit.... Companies with little patent portfolio and big genertic type will benefit...
"Then there there is Kyle Bass and his hedge fund,who as I understand it is short Acorda ,filing a inter partes review with the patent board on the basis that one of the ingredients of Ampyra is too obvious to be patented.Don't think this is a problem ."
It appears as though Bass has painted a target on the "drug industry's" back. From what I understand he seems to think company discovery efforts are not entitled to patent protection and, by extension, not allowed to earn a profit on their research efforts. In other words, a financial bomb thrower. Unfortunately he, like so many hedge fund managers are able to gain a national audience through CNBC , cause a stir with a few out of context comments, and then reap the rewards from the ensuing stock action.
Apparently ACOR happens to be his most recent target.....good for Bass's short position, not good for ACOR due to the annoyance of what is very likely a frivolous lawsuit..... jmho
It appears as though many investors are afraid Ampyra will lose patent protection sooner than later.There are 8 generic drug makers challenging the patents.Then there there is Kyle Bass and his hedge fund,who as I understand it is short Acorda ,filing a inter partes review with the patent board on the basis that one of the ingredients of Ampyra is too obvious to be patented.Don't think this is a problem .Ampyra is covered by numerous patents so if they lose one patent,I don't think anyone could make a generic copy.But to be honest ,it has made me nervous.I'm a buy and hold investor and the thought of selling did cross my mind.
Looks like we will be getting back to 40 in the near future, I should have picked up some more at the dip.
I did not listen to CC, wondering if guidance was positive?
Why would Kyle Bass, a hedge fund manager, file a patent violation against ACOR ? He's short ! Activist hedgie get some air play on CNBC and a stock collapses. Something VERY wrong with this picture.
There was a brief mention on CNBC that Kyle Bass had filed a lawsuit against ACOR accusing it of patent violation. That was the cause of the selloff.